London, UK, 22 February 2021.
Thirty Holdings Limited (“30 Technology”) is delighted to announce a multi-year research and development partnership to develop a new medicine to treat drug-resistant strains of tuberculosis (TB). This is the first of many development partnerships. 30 Technology is a clinical stage pharmaceutical company with a platform portfolio based on its proprietary multi-modal nitric oxide generating technology. Products are in development and in clinical trials to target multiple chronic respiratory diseases, bacterial and viral infections.
Commenting on the agreement, 30 Technology’s Executive Director, Justin Barnes said “we are delighted to have entered into our first external research and development agreement. During the past 2 years we have built a first-class in-house research capability and in collaboration with global TB experts demonstrated significant in-vitro efficacy against both hyper virulent drug-sensitive and multi-drug resistant strains of TB.”
TB is the leading killer among diseases caused by an infectious agent worldwide and the leading killer of people with HIV infection Indeed, worldwide, TB remains one of the top 10 causes of death. Globally, 3.5% of new TB cases and 18% of previously treated cases had multidrug-resistant TB, highlighting the need for more sustainable methods of treatment (WHO, 2018). The transmission of drug resistant tuberculosis is a particular challenging in low resource settings where isolation of infectious patients is difficult and infection control systems are relatively weak. According to the WHO (2019), 20% of all patients diagnosed with active TB disease each year are infected with M. tuberculosis strains that are drug-resistant to various degrees: 10% are mono-resistant, and the other 10% are multi-drug resistant (MDR) or extensively drug resistant (XDR).
RESP301 is a NO-generating liquid designed to release NO in situ in the upper airways and deep in the alveolar spaces. RESP301 is an admixture solution of two precursor solutions mixed at point of care for immediate inhaled administration via a handheld nebuliser and has specific advantages in treating a range of respiratory viruses, including SARS-CoV-2. In laboratory testing, RESP301 has also demonstrated potent activity against various influenza virus strains, rhinovirus and coronavirus. It has also shown high in vitro activity against other respiratory pathogens, both viral and bacterial. The novel concept for RESP301 is that it will restore the levels of NO in the lungs with a dual action of both killing virus and bacteria and boosting the host response against these pathogenic microbes.
About 30 Technology
30 Technology is a privately owned biopharmaceutical company developing proprietary NO-generating technologies. The products that 30 Technology has developed have very broad application in many areas of medicine.
For further information, please contact: firstname.lastname@example.org